Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionGAMMA Investing LLC
Latest Disclosed Ownership2,507 shares
Latest Disclosed Value $ 1,937,008
GAMMA Investing LLC reports 14.95% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 6, 2026 - GAMMA Investing LLC filed a 13F-HR form disclosing ownership of 2,507 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $1,937,008 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 5, 2026 disclosing 2,181 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 14.95% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-06 2026-03-31 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 2,507 326 14.95 1,937 15.09 0.0904
2026-01-05 2025-12-31 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 2,181 455 26.36 1,683 73.51 0.0846
2025-10-02 2025-09-30 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 1,726 451 35.37 970 44.99 0.0535
2025-07-14 2025-06-30 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 1,275 -11 -0.86 669 -17.91 0.0423
2025-04-15 2025-03-31 13F/A-1 REGENERON PHARMACEUTICALS COM Common Stock 75886F107 1,286 379 41.79 816 26.16 0.0612
2025-04-07 2025-03-31 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 815,620 814,713 1 0.0069
2025-01-03 2024-12-31 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 907 -529 -36.84 646 -57.19 0.0551
2024-10-04 2024-09-30 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 1,436 353 1,510 0.1497
2024-10-07 2024-09-30 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 1,436 353 32.59 1,510 32.60 0.1497
2024-07-02 2024-06-30 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 1,083 199 22.51 1,138 33.88 0.1551
2024-04-05 2024-03-31 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 884 154 21.10 851 23.55 0.1733
2024-02-01 2023-12-31 13F REGENERON PHARMACEUTICALS COM Common Stock 75886F107 730 730 688 0.1864
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.